BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have received an average rating of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $140.0314.

Several research firms recently issued reports on BNTX. Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research note on Friday. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $115.00 to $142.00 in a research note on Friday, January 16th. Bank of America dropped their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a research note on Wednesday, December 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $140.00 target price on shares of BioNTech in a research note on Thursday, December 11th.

BioNTech Stock Performance

NASDAQ:BNTX opened at $115.98 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. The stock has a market capitalization of $26.12 billion, a PE ratio of -44.10 and a beta of 1.40. BioNTech has a fifty-two week low of $81.20 and a fifty-two week high of $126.77. The company has a fifty day moving average of $99.39 and a two-hundred day moving average of $103.62.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The company had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter last year, the business earned $0.81 EPS. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. As a group, research analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Several large investors have recently bought and sold shares of BNTX. Freestone Capital Holdings LLC acquired a new stake in BioNTech in the 4th quarter valued at about $753,000. Banque Pictet & Cie SA boosted its holdings in shares of BioNTech by 12.6% during the 4th quarter. Banque Pictet & Cie SA now owns 21,735 shares of the company’s stock worth $2,069,000 after purchasing an additional 2,424 shares during the last quarter. SG Americas Securities LLC grew its position in shares of BioNTech by 1,664.6% in the fourth quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock valued at $34,780,000 after purchasing an additional 344,630 shares in the last quarter. Arlington Capital Management Inc. acquired a new stake in shares of BioNTech in the fourth quarter valued at approximately $248,000. Finally, Hudson Bay Capital Management LP lifted its position in BioNTech by 36.7% during the third quarter. Hudson Bay Capital Management LP now owns 205,004 shares of the company’s stock worth $20,217,000 after buying an additional 55,004 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.